LK101 and Likang’s Research Pipeline: Read the Names Correctly
LK101, LK201, LK301, LK302 and LK401 are separate names in Likang’s research brochure. A pipeline label is not an offer of available treatment. This guide, checked on 10 October 2026, explains the manufacturer’s labels while leaving current development status and individual eligibility unverified. Use it to ask which exact programme a discussion concerns.
Start with the exact LK101 label
On original page1, Likang’s undated English brochure describes LK101 as a personalized neoantigen mRNA-DC vaccine. It says personalized neoantigen mRNA is delivered through the patient’s own dendritic cells. The supplied technical manual describes the same mRNA-DC approach. These are manufacturer descriptions, not evidence of an individual outcome.
Keep the other programmes separate
The table below follows the separate names and descriptions on original page1 of the brochure. It is a reading aid for that source, not a comparison of treatment results.
What this brochure does not establish
The brochure’s programme names do not confirm current development stages, recruitment, general marketing authorization or available appointments. This guide does not independently verify those matters and does not offer LK201, LK301, LK302 or LK401 treatment. Do not transfer an LK101 description to another programme simply because the names look similar.
Questions to take into an enquiry
Uwell coordinates enquiries and medical-record preparation. The clinical team decides eligibility and treatment. Ask for a programme-specific explanation before treating a research description as a care plan.
- Which exact product or research programme is being discussed?
- Which current source describes its development or authorization status?
- Who will confirm whether the proposed pathway applies to my case?
Source: Likang brochure, original page1, and supplied technical manual, printed page11.
| Programme | Manufacturer’s brochure description |
|---|---|
| LK201 | Personalized multi-target neoantigen-specific T-cell therapy |
| LK301 | Shared-antigen TCR-T programme for mutation-positive tumours |
| LK302 | Shared-antigen TCR-T programme for antigen-expressing tumours |
| LK401 | Personalized neoantigen TCR-T programme |
Frequently asked questions
Is LK201 another name for LK101?
Does this pipeline list show treatments I can book?
Who decides whether a programme is relevant to my care?
This article was produced with AI assistance and reviewed against Uwell Cloud editorial and compliance standards.